New range of lung-on-chip technologies represent the vital properties of lung tissue

According to the National Institutes of Health, respiratory viruses are the most frequent cause of disease and death in humans, a fact highlighted by the COVID-19 pandemic. Despite the potential to cause severe disease, over 70% of viral infections remain asymptomatic.

Animal models have been used widely to understand how these viruses infect the host and how the host responds to prevent infection and the onset of diseases. Data based on animal models, however, do not always apply well to humans, given the variability in species and genetics.

In Biomicrofluidics, by AIP Publishing, researchers from Ege University and the University of Nottingham review a range of lung-on-chip technologies that represent the vital properties of lung tissue and are capable of recapitulating the fundamental aspects of various pathologies.

"Lung-on-chip platforms are able to reconstruct the multicellular architecture, the physiochemical microenvironment, and the tissue-tissue interface of the human lung in vitro," said author Ozlem Yesil-Celiktas.

The researchers reviewed various state-of-the-art lung-on-chips and their applications in examining, diagnosing, and treating human viruses, including the coronavirus that causes COVID-19. Different platforms focus on different parts of the lung functions, such as small airway-on-chips and lung alveolus chips.

The knowledge and expertise accumulated through the development of physiologically relevant lung-on-chip models paves the way to use these models to study the interaction of several human respiratory viruses with the airway epithelium and alveolus in an organ-relevant setting.

The current pandemic, which spread to almost every continent in just a few months, makes us realize how much we need a practical, humanized platform to expedite the trials for potential antiviral drugs and vaccines."

Ozlem Yesil-Celiktas, Study Author, American Institute of Physics

Considering new research showing one of the aftereffects of COVID-19-related pneumonia is pulmonary fibrosis, the lung-on-chip systems, which focus on lung fibrosis, enable a deeper understanding of disease mechanisms and related immune and technological responses.

Despite the advantages, the lack of vascularity and integration with external immune cells means these organ-chip platforms require the integration of these components to the microchips, not only for viral infections but also for other pathologies.

Going forward, the researchers will integrate modular sensing apparatus to provide online monitoring opportunities along with diagnostic outcomes. Such biomimetic systems also enable high-resolution and real-time imaging, as well as in-vitro toxicological analysis or measurements of metabolic activities of living cells.

Journal reference:

Saygili, E., et al. (2021) Human lung-on-chips: Advanced systems for respiratory virus models and assessment of immune response. Biomicrofluidics.


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New influenza vaccine strategies aim to enhance protection with T-cell responses